4DMedical to Distribute RevealAI-Lung in the US, Europe, Australia and New ZealandSeattle, WA – August 5, 2026 – RevealDx, a leader in AI characterization of lung nodules, announced today, following World Lung Cancer Day, a distribution agreement and strategic investment of $3.4 million by 4DMedical (ASX: 4DX), expanding access to its flagship product, RevealAI-Lung. In the transaction with 4DMedical, Chestnut Partners, Inc. served as the exclusive financial advisor to RevealDx. Contextflow offers advanced chest CT technologies that automate the identification of lung nodules. “As we recognize World Lung Cancer Day, this milestone underscores our commitment to helping clinicians identify potentially malignant lung nodules earlier and with greater confidence. Andreas Fouras, Founder and CEO of 4DMedical, said, “For 4DMedical, this is about more than adding products.